TYP-III-CRISPR/CAS-BASIERTE DIAGNOSTIK

European patent · EP3987058 · In force

Register entry

Publication number
EP3987058
Application number
EP20744159
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 19, 2020
Published
Apr 27, 2022
Granted
Nov 6, 2024
Protection ends at the latest
Jun 18, 2040
Next annual fee due
Jun 30, 2027
IPC classes
C12Q 1/682 (2018.01)
Priority
EP 19181371 19.06.2019
EP 20168487 07.04.2020
PCT application
PCT/NL2020/050400 19.06.2020
PCT publication
WO2020/256553 24.12.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 13, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 13.07.2026

  2. Sep 17, 2025

    Change

    Published in Swissreg on 17.09.2025

  3. Jul 17, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 17.07.2025

  4. Dec 9, 2024

    Agent entered

    Representative
    HGF GmbH, OBC Suisse AG, Aeschengraben 29, 4051 Basel

    Published in Swissreg on 09.12.2024

  5. Nov 6, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 06.11.2024

Parties

Holder

SCOPE BIOSCIENCES B.V.

Bronland 12B-1, 6708 WH Wageningen, NL

Agent

HGF GmbH

HGF GmbH OBC Suisse AG

Aeschengraben 29, 4051 Basel

Inventor

STEENS, Aiko Jurre

6701 AJ Wageningen, NL

PRINSEN, Stijn Hendrikus Petrus

6708 PG Wageningen, NL

VAN DER OOST, John

6871HZ Renkum, NL

STAALS, Raymond Hubert Josèphe

6711NZ Ede, NL

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.